Updated:
Aardvark Therapeutics
Aardvark Therapeutics develops oral therapies that activate gut bitter taste receptors to suppress hunger in Prader-Willi syndrome and obesity.
Aardvark Therapeutics
Aardvark Therapeutics launched in 2017 with a narrow but chemically novel premise: activate bitter taste receptors (TAS2Rs) in the gastrointestinal tract to stimulate the body's own satiety hormones without engaging the central nervous system. CEO Tien-Li Lee assembled a team to develop ARD-101, a small-molecule oral therapy designed to suppress the insatiable hunger that defines Prader-Willi syndrome. The firm operates from San Diego. Aardvark's pipeline concentrates on severe hyperphagia and related metabolic conditions. ARD-101 acts on enteroendocrine cells lining the gut, triggering cholecystokinin and GLP-1 release — a peripheral approach that avoids the neuropsychiatric side effects common with centrally acting appetite drugs. The company completed a Phase 2 proof-of-concept trial in Prader-Willi syndrome and intends to explore broader obesity indications where the mechanism may also apply. The Series C financing in early 2024, led by Decheng Capital with participation from Cormorant Asset Management and Surveyor Capital (a Citadel unit), earmarked capital to advance ARD-101 into late-stage trials (per the firm, January 2024). Holdings span the rare-disease and metabolic sectors, with the United States as the primary clinical trial and regulatory geography. The company has disclosed cumulative funding exceeding $120 million. In November 2023, Aardvark reported positive topline Phase 2 data showing statistically significant reductions in hyperphagia and weight versus placebo in Prader-Willi patients, positioning the firm for end-of-Phase 2 regulatory meetings (per the firm, November 2023). No adjacent vehicles or philanthropic structures have been publicly disclosed. Aardvark's structural distinction lies in its peripheral mechanism of action — all major GLP-1 and appetite-suppressant drugs to date either act centrally or deliver exogenous hormones. If ARD-101 succeeds, it would represent the first satiety therapeutic built around endogenous gut signaling pathways. The single-compound, single-pipeline architecture is lean by design, typical of early- to mid-stage biotech, but places outsized binary outcomes on one Phase 3 program.
General information
Firm type
other
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Tien-Li Lee
Chief Executive Officer
Sector focus
Frequently asked questions
What is Aardvark Therapeutics' lead clinical program?
ARD-101 is an oral small molecule designed to activate TAS2Rs — bitter taste receptors — located on endocrine cells in the gut. This activation triggers the release of the body's own satiety peptides, including CCK and GLP-1, without crossing the blood-brain barrier. The compound is currently completing Phase 2 development for hyperphagia associated with Prader-Willi syndrome.
Who runs investment and scientific strategy at Aardvark Therapeutics?
Tien-Li Lee is the founder and CEO, directing both the scientific roadmap and corporate strategy. The board and scientific advisory members have not been extensively catalogued in public filings, reflecting typical early clinical-stage biotech opacity. The Series C investor syndicate — Decheng Capital, Cormorant Asset Management and Surveyor Capital — holds board representation typical of venture-backed biotech.
What therapeutic areas does Aardvark target, and which does it avoid?
Aardvark focuses exclusively on metabolic and endocrine disorders driven by hyperphagia — specifically Prader-Willi syndrome and broader obesity indications. It does not pursue oncology, neurology, immunology or other therapeutic areas. The firm has also signaled it is not developing centrally acting appetite suppressants, deliberately avoiding the neuropsychiatric side effects associated with drugs that modulate hunger via the brain.
How is Aardvark Therapeutics funded, and what is its capital structure?
Aardvark is venture-capital backed, having raised over $120 million in disclosed equity rounds. The most recent financing was an $85 million Series C in early 2024 led by Decheng Capital. As a private clinical-stage company, it does not report AUM or operate a fund structure — capital is deployed directly into clinical trials, manufacturing scale-up and regulatory activity for ARD-101.
What distinguishes Aardvark's mechanism from existing GLP-1 obesity drugs?
Existing GLP-1 receptor agonists such as semaglutide and tirzepatide introduce exogenous peptides that mimic or enhance incretin signaling, often with CNS penetration. ARD-101 works peripherally by agonizing bitter taste receptors in the gut lumen, prompting the body's own enteroendocrine cells to secrete endogenous satiety hormones. This gut-restricted pharmacology is designed to achieve appetite suppression without systemic exposure or neurological side effects.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: